Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials

PLoS Neglected Tropical Diseases

Volumn 3, Issue 2, 2009, Pages

  Kim, Dae Hyun ^a   Chung, Hye Jin ^b   Bleys, Joachim ^c   Ghohestani, Reza F ^d,e  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d University of Texas Health Science Center   (United States)

^e Texas Institute of Dermatology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMONY DERIVATIVE; MEGLUMINE ANTIMONATE; METHYLBENZETHONIUM CHLORIDE; PAROMOMYCIN; PLACEBO; STIBOGLUCONATE SODIUM; ANTIPROTOZOAL AGENT; BENZETHONIUM CHLORIDE; DRUG DERIVATIVE; METHYLBENZETHONIUM;

APPLICATION SITE BURNING; APPLICATION SITE EDEMA; APPLICATION SITE ERYTHEMA; APPLICATION SITE INFLAMMATION; APPLICATION SITE PAIN; APPLICATION SITE PRURITUS; APPLICATION SITE REACTION; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LIVER DYSFUNCTION; META ANALYSIS; MONOTHERAPY; MYALGIA; RANDOMIZED CONTROLLED TRIAL; SKIN LEISHMANIASIS; SYSTEMATIC REVIEW; SYSTEMIC DISEASE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTIPROTOZOAL AGENTS; BENZETHONIUM; HUMANS; LEISHMANIASIS, CUTANEOUS; PAROMOMYCIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 65549169902     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pntd.0000381     Document Type: Article

References (52)

1. World Health Organization (2007) Leishmaniasis. Available: http://www.who.int/leishmaniasis/en via Internet. Accessed 17 Jun 2007.
2. Buffet PA, Morizot G (2003) Cutaneous leishmaniasis in France: towards the end of injectable therapy? Bull Soc Pathol Exot 96: 383-8.
3. Armijos RX, Weigel MM, Calvopina M, Mancheno M, Rodriguez R (2004) Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis. Acta Trop 91: 153-160.
4. Correia D, Macedo VO, Carvalho EM, Barral A, Magalhaes AV, et al. (1996) Comparative study between meglumine antimoniato, pentamidine isothianate and aminosidine sulphate, in the treatment cutaneous primary lesions, caused by Leishmania (Viannia) braziliensis (L(V)b). Rev Soc Bras Med Trop 29: 447-453.
5. Hepburn NC, Tidman MJ, Hunter JA (1994) Aminosidine (paromomycin) versus sodium stibogluconate for the treatment of American cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 88: 700-703.
6. Soto J, Fuya P, Herrera R, Berman J (1998) Topical paromomycin/ methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study. Clin Infect Dis 26: 56-58.
7. Grogl M, Thomason TN, Franke ED (1992) Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease. Am J Trop Med Hyg 47: 117-126.
8. Bailey MS, Lockwood DN (2007) Cutaneous leishmaniasis. Clin Dermatol 25: 203-211.
9. Akovbyan AA, Mukhamedov SM (1968) Treatment of cutaneous leishmaniasis of acutely necrotizing type (Borovsky disease) with monomycin. Trop Dis Bull 65: 987.
10. Neal RA (1968) The effect of antibiotics of the neomycin group on experimental cutaneous leishmaniasis. Ann Trop Med Parasitol 62: 54-62.
11. El-On J, Greenblatt CL (1983) An in vitro model for testing the effect of anti-leishmanial drugs of possible use in topical treatment. Curr Ther Res Clin Exp 33: 660-669.
12. El-On J, Jacobs GP, Witztum E, Greenblatt CL (1984) Development of topical treatment for cutaneous leishmaniasis caused by Leishmania major in experimental animals. Antimicrob Agents Chemother 26: 745-751.
13. El-On J, Livshin R, Even-Paz Z, Hamburger D, Weinrauch L (1986) Topical treatment of cutaneous leishmaniasis. J Invest Dermatol 87: 284-288.
14. Bryceson AD, Murphy A, Moody AH (1994) Treatment of 'Old World' cutaneous leishmaniasis with aminosidine ointment: results of an open study in London. Trans R Soc Trop Med Hyg 88: 226-228.
15. Neal RA, Murphy AG, Olliaro P, Croft SL (1994) Aminosidine ointments for the treatment of experimental cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 88: 223-225.
16. Arana BA, Mendoza CE, Rizzo NR, Kroeger A (2001) Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala. Am J Trop Med Hyg 65: 466-470.
17. Faghihi G, Tavakoli KR (2003) Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate. Clin Exp Dermatol 28: 13-16.
18. Moosavi Z, Nakhli A, Rassaii S (2005) Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis. Int J Dermatol 44: 1064-1065.
19. Berman J (2005) Recent developments in leishmaniasis: Epidemiology, diagnosis, and treatment. Curr Infect Dis Rep 7: 33-38.
20. Hepburn NC, Siddique I, Howie AF, Beckett GJ, Hayes PC (1994) Hepatotoxicity of sodium stibogluconate therapy for American cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 88: 453-455.
21. Soto J, Grogl M, Berman J, Olliaro P (1994) Limited efficacy of injectable aminosidine as single-agent therapy for Colombian cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 88: 695-698.
22. Asilian A, Jalayer T, Nilforooshzadeh M, Ghassemi RL, Peto R, et al. (2003) Treatment of cutaneous leishmaniasis with aminosidine (paromomycin) ointment: double-blind, randomized trial in the Islamic Republic of Iran. Bull World Health Organ 81: 353-359.
23. Soto J, Hernandez N, Mejia H, Grogl M, Berman J (1995) Successful treatment of New World cutaneous leishmaniasis with a combination of topical paromomycin/methylbenzethonium chloride and injectable meglumine antimonate. Clin Infect Dis 20: 47-51.
24. Gardlo K, Horska Z, Enk CD, Rauch L, Megahed M, et al. (2003) Treatment of cutaneous leishmaniasis by photodynamic therapy. J Am Acad Dermatol 48: 893-896.
25. Mukhopadhaya A, Mendecki J, Dong X, Liu L, Kalnicki S, et al. (2007) Localized hyperthermia combined with intratumoral dendritic cells induces systemic antitumor immunity. Cancer Res 67: 7798-7806.
26. Johnson SM, Roberson PK, Horn TD (2001) Intralesional injection of mumps or Candida skin test antigens: a novel immunotherapy for warts. Arch Dermatol 137: 451-455.
27. Ozgoztasi O, Baydar I (1997) A randomized clinical trial of topical paromomycin versus oral ketoconazole for treating cutaneous leishmaniasis in Turkey. Int J Dermatol 36: 61-63.
28. Asilian A, Davami M (2006) Comparison between the efficacy of photodynamic therapy and topical paromomycin in the treatment of Old World cutaneous leishmaniasis: a placebo-controlled, randomized clinical trial. Clin Exp Dermatol 31: 634-637.
29. Iraji F, Sadeghinia A (2005) Efficacy of paromomycin ointment in the treatment of cutaneous leishmaniasis: Results of a double-blind, randomized trial in Isfahan, Iran. Ann Trop Med Parasitol 99: 3-9.
30. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
31. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-1558.
32. Asilian A, Jalayer T, Whitworth JA, Ghasemi RL, Nilforooshzadeh M, et al. (1995) A randomized, placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran. Am J Trop Med Hyg 53: 648-651.
33. Shazad B, Abbaszadeh B, Khamesipour A (2005) Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major. Eur J Dermatol 15: 85-87.
34. Salah AB, Zakraoui H, Zaatour A, Ftaiti A, Zaafouri B, et al. (1995) A randomized, placebo-controlled trial in Tunisia treating cutaneous leishmaniasis with paromomycin ointment. Am J Trop Med Hyg 53: 162-166.
35. Neva FA, Ponce C, Ponce E, Kreutzer R, Modabber F, et al. (1997) Non-ulcerative cutaneous leishmaniasis in Honduras fails to respond to topical paromomycin. Trans R Soc Trop Med Hyg 91: 473-475.
36. El-Safi SH, Murphy AG, Bryceson ADM, Neal RA (1990) A double-blind clinical trial of the treatment of cutaneous leishmaniasis with paromomycin ointment. Trans R Soc Trop Med Hyg 84: 690-691.
37. El-On J, Halevy S, Grunwald MH, Weinrauch L (1992) Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: A double-blind control study. J Am Acad Dermatol 27: 227-231.
38. El-On J, Messer G (1986) Leishmania major: antileishmanial activity of methylbenzethonium chloride. Am J Trop Med Hyg 35: 1110-1116.
39. El-On J, Jacobs GP, Weinrauch L (1988) Topical chemotherapy of cutaneous leishmaniasis. Parasitol Today 4: 76-81.
40. Goncalves GS, Fernandes AP, Souza RC, Cardoso JE, De Oliveira-Silva F, et al. (2005) Activity of a paromomycin hydrophilic formulation for topical treatment of infections by Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis. Acta Trop 93: 161-167.
41. Grogl M, Schuster BG, Ellis WY, Berman JD (1999) Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (Aminosidine) and gentamicin. J Parasitol 85: 354-359.
42. Lecoeur H, Buffet P, Morizot G, Goyard S, Guigon S, et al. (2007) Optimization of topical therapy for Leishmania major localized cutaneous leishmaniasis using a reliable C57BL/6 model. PLoS Negl Trop Dis 1: e34. doi:10.1371/journal.pntd.0000034.
43. Krause G, Kroeger A (1994) Topical treatment of American cutaneous leishmaniasis with paramomycin and methylbenzethonium chloride: a clinical study under field conditions in Ecuador. Trans R Soc Trop Med Hyg 88: 92-94.
44. Neal RA, Allen S, McCoy N, Olliaro P, Croft SL (1995) The sensitivity of Leishmania species to aminosidine. J Antimicrob Chemother 35: 577-584.
45. Weinrauch L, Cawich F, Craig P, Sosa JX, El-On J (1993) Topical treatment of New World cutaneous leishmaniasis in Belize: a clinical study. J Am Acad Dermatol 29: 443-446.
46. Khatami A, Firooz A, Gorouhi F, Dowlati Y (2007) Treatment of acute Old World cutaneous leishmaniasis: a systematic review of the randomized controlled trials. J Am Acad Dermatol 57: 335.e1-e29.
47. Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, et al. (2007) Cutaneous leishmaniasis. Lancet Infect Dis 7: 581-596.
48. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, et al. (2001) The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 134: 663-694.
49. Moher D, Schulz KF, Altman DG (2001) The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med 134: 657-662.
50. Sterne JA, Egger M, Smith GD (2001) Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis. BMJ 323: 101-105.
51. Sutton AJ, Duval SJ, Tweedie RL, Abrams KR, Jones DR (2000) Empirical assessment of effect of publication bias on meta-analyses. BMJ 320: 1574-1577.
52. Berman JD (2005) Clinical status of agents being developed for leishmaniasis. Expert Opin Investig Drugs 14: 1337-1346.